BDSX logo

Biodesix, Inc. Stock Price

NasdaqGM:BDSX Community·US$63.2m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

BDSX Share Price Performance

US$7.90
-20.10 (-71.79%)
US$2.00
Fair Value
US$7.90
-20.10 (-71.79%)
295.0% overvalued intrinsic discount
US$2.00
Fair Value
Price US$7.90
AnalystHighTarget US$2.00
AnalystConsensusTarget US$35.00
AnalystLowTarget US$1.50

BDSX Community Narratives

AnalystHighTarget·
Fair Value US$2 295.0% overvalued intrinsic discount

Precision Medicine And AI Will Fuel Diagnostic Evolution

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$35 77.4% undervalued intrinsic discount

Digital Integration And Expanded Lung Diagnostics Will Broaden Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value US$1.5 426.7% overvalued intrinsic discount

Lung Diagnostics Will Face Regulatory Delays While Modest Progress Unfolds

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Snowflake Analysis

Undervalued with moderate risk.

5 Risks
3 Rewards

Biodesix, Inc. Key Details

US$80.2m

Revenue

US$16.2m

Cost of Revenue

US$64.0m

Gross Profit

US$103.5m

Other Expenses

-US$39.5m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-4.97
79.82%
-49.31%
-2,736.5%
View Full Analysis

About BDSX

Founded
2005
Employees
273
CEO
Scott Hutton
WebsiteView website
www.biodesix.com

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Recent BDSX News & Updates

US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results

Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results

Recent updates

No updates